Down regulation of N-acetylglucosaminyltransferase V facilitates all-trans retinoic acid to induce apoptosis of human hepatocarcinoma cells

被引:11
|
作者
Guo, Peng
Chen, Hai-jiao
Wang, Qiu-yan
Chen, Hui-Li [1 ]
机构
[1] Fudan Univ, Shanghai Med Coll, Dept Biochem, Minist Hlth,Key Lab Glycoconjugate Res, Shanghai 200032, Peoples R China
[2] Fudan Univ, Zhong Shan Hosp, Dept Urol, Shanghai 200032, Peoples R China
关键词
all-trans retinoic acid (ATRA); apoptosis; caspase; Bcl-2; family; N-acetylglucosaminyltransferase V (GnT-V); protein kinase B (PKB/Akt);
D O I
10.1007/s11010-005-9022-5
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
After N-acetylglucosaminyltransferase V (GnT-V) activity was down-regulated by the transfection of its antisense cDNA(GnTV-AS), apoptosis of H7721 cells was appeared and the apoptosis induced by 80 mu M all-transretinoic acid (ATRA) was facilitated, while ATRA itself could not induce apparent apoptosis in mock cells transfected with the vector. In the study of the molecular mechanism of this phenomenon, it was found that GnTV-AS reduced the expressions of anti-apoptotic proteins, such as phosphorylated protein kinase B and phosphorylated Bad as well as Bcl-2 and Bcl-X (L), and elevated those of pro-apoptotic proteins, including Bax, full length caspase-3 and its activated fragments as well as anti-oncoprotein p53. In the contrast, ATRA up regulated the expressions of Bax and activated caspase-3 fragments only. After the GnTV-AS transfected cells were treated with ATRA, phosphorylated PKB and Bad were further decreased, while Bax and activated caspase-3 fragment were further increased, leading to the enhanced apoptosis in flow-cytometry analysis when compared with GnTV-AS cells not treated with ATRA. It was speculated that the decreased phospho-Bad resulted from the reduced phospho-PKB and the up regulation of p53 caused the elevated activity of Bax. The increased active caspase-3 was the consequence of the elevated Bax/ Bcl-2(Bcl-X-L) activity ratio in the cells.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 50 条
  • [31] Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes
    Le Vee, Marc
    Jouan, Elodie
    Stieger, Bruno
    Fardel, Olivier
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 48 (4-5) : 767 - 774
  • [32] Effect of all-trans retinoic acid on differentiation of osteosarcoma cells
    CHEN Ying-qian
    YANG Bo
    HE Qiao-jun
    YING Mei-dan
    中国药理学与毒理学杂志, 2019, (10) : 782 - 782
  • [33] Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells
    Barna, G
    Sebestyén, A
    Weischede, S
    Peták, I
    Mihalik, R
    Formelli, F
    Kopper, L
    ANTICANCER RESEARCH, 2005, 25 (6B) : 4179 - 4185
  • [34] Regulation of RPE barrier function by all-trans retinoic acid in myopia
    Mao, Junfeng
    Liu, Shuangzhen
    NEUROSCIENCE LETTERS, 2014, 568 : 17 - 22
  • [35] Regulation of Gli activity by all-trans retinoic acid in mouse keratinocytes
    Goyette, P
    Allan, D
    Peschard, P
    Chen, CF
    Wang, W
    Lohnes, D
    CANCER RESEARCH, 2000, 60 (19) : 5386 - 5389
  • [37] Effects of all-trans retinoic acid on proliferation of human aorta smooth muscle cells
    Liu, GX
    Li, CX
    Zeng, LF
    Wang, YC
    CHINESE SCIENCE BULLETIN, 1999, 44 (05): : 448 - 451
  • [38] Down-regulation of ID2 by all-trans retinoic acid in monocytic leukemia cells (THP-1)
    Wågsäter, D
    Sirsjö, A
    Dimberg, J
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (03) : 471 - 475
  • [39] All-trans retinoic acid is dedifferentiating to human mast cells independent of their stage of maturation
    Thienemann, F
    Guhl, S
    Rex, C
    Kirchhof, L
    Artuc, M
    Zuberbier, T
    Henz, BM
    Babina, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
  • [40] EFFECTS OF ALL-TRANS RETINOIC ACID ON THE MORPHOLOGY OF HUMAN EPIDERMAL-CELLS INVITRO
    KONOHANA, I
    HASHIMOTO, T
    DYKES, PJ
    MARKS, R
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 1987, 279 (07) : 459 - 464